|
Teva is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients.
HIGHLIGHTS
- With operations in over 50 countries and approximately 26,000 employees worldwide, Teva Pharmaceuticals offers the widest range of cost-effective pharmaceuticals, both generic and branded, to millions of consumers, customers and healthcare providers
- Teva is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.
- Teva has production facilities in Israel, North and Latin America and Europe, and operates through a carefully tailored network of worldwide subsidiaries.
- Teva markets and develops innovative drugs for specialized markets and produces generic drugs in all major therapeutic categories.
- The pharmaceuticals division contributes 90% of Teva’s Revenues.
- Teva owns the exclusive license to develop the drug, Copaxane, (glatiramer acetate) for the treatment of Multiple Sclerosis which is marketed and sold in 47 countries.
PRODUCTS AND ACQUISITIONS
· 2008-Teva acquires Barr Pharmaceuticals.
· 2008-USFDA granted final approval for generic Fosomax tablets.
· 2008-USFDA granted tentative approval for generic Flomax and Prevaid Delayed capsules.
· 2008-Teva acquires CoGenesys, a privately held biopharmaceutical company.
· 2007-USFDA approves generic Dostine and Alprazola tablets.
· 2006-Teva launches sales of Zoloft and generic Wellbutrin tablets.
· 2006-Teva acquires IVAX Corporation.
· 2004-Teva completes the acquisition of US company Sicor, for $3.4 billion, representing the largest-ever deal by an Israeli company to date.
· 2008-160 product applications awaiting final FDA approval.
Returns:
- Net Income for 2007 reached $1.952 billion (+5% over 2006)
- Net sales for 2007 were $9.4 billion
|